Want to see AU:TLX full AI Analyst Report?

Telix Pharmaceuticals (TLX) Price & Analysis

631 Followers

TLX Stock Chart & Stats

AU$14.66

-AU$0.38(-2.59%)

At close: Jul 27 4:00 PM EDT

AU$14.66

-AU$0.38(-2.59%)

Day’s Range― - ―

52-Week RangeAU$8.26 - AU$19.07

Previous CloseN/A

Volume2.26M

Average Volume (3M)1.87M

Market Cap

AU$5.31B

Enterprise ValueAU$6.39K

Total Cash (Recent Filing)AU$363.61M

Total Debt (Recent Filing)AU$836.98M

Price to Earnings (P/E)113.0

Beta1.13

Next Earnings

Feb 19, 2027

EPS Estimate

0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.14

Shares Outstanding339,784,300

10 Day Avg. Volume1,472,861

30 Day Avg. Volume1,873,147

Financial Highlights & Ratios

PEG Ratio2.81

Price to Book (P/B)6.08

Price to Sales (P/S)3.04

P/FCF Ratio-44.20

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$25.17

Price Target Upside71.71% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)0.03

Revenue Forecast (FY)AU$984.01M

Bulls Say, Bears Say

Bulls Say

Strong Revenue GrowthSustained double-digit growth, led by Precision Medicine, demonstrates strong product adoption and commercial execution. Management’s maintained full-year guidance and expectation of landing near the upper end support continued revenue expansion over the next several quarters.

Improving Margins And ProfitabilityHigher gross margins and operating leverage indicate improving product economics as the commercial base scales. Cost discipline, rising EBITDA and positive H1 net profit provide evidence that growth can increasingly translate into earnings rather than relying solely on expansion.

Growing Market Position And CapabilityRepeated share gains and international expansion strengthen Telix’s commercial position in radiopharmaceutical imaging. Manufacturing and distribution investments, including RLS integration, can improve supply reliability and support broader product and therapeutic rollout.

Bears Say

Rising LeverageA faster increase in debt than equity reduces financial flexibility and raises refinancing and interest burden risks. This is especially important while earnings remain volatile, because weaker profitability could constrain investment capacity or increase dependence on external funding.

Weak Recent Cash ConversionThe reversal to negative operating and free cash flow suggests that growth is currently absorbing substantial working capital or investment. Persistent weak conversion could pressure funding needs and limit the company’s ability to finance pipeline expansion internally.

Regulatory And Investment Execution RiskThe Zircaix setback delays a potential product contribution and highlights manufacturing-readiness risk in a regulated business. At the same time, elevated R&D investment increases execution and funding requirements before pipeline programs can generate commercial returns.

Telix Pharmaceuticals News

Telix Pharmaceuticals: Buy Rating Reiterated with Unchanged $31 Target Ahead of Key Pixclara Regulatory Catalyst

Telix Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Laura Sutcliffe from...

5d ago

Telix outlines H1 2026 progress in radiopharmaceutical and precision medicine units

The latest update is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix Pharmaceuticals released an interim H1 2026...

5d ago

Telix swings to profit on strong U.S. radiopharmaceutical sales

An update from Telix Pharmaceuticals ( ($AU:TLX) ) is now available. Telix Pharmaceuticals reported robust half-year revenue growth...

5d ago

Telix Advances PDGFR Alpha Imaging Program With New Phase 1 Trial Update

Telix Pharmaceuticals Ltd. ($TLPPF) announced an update on their ongoing clinical study. The study An Open-label, Phase 1...

10d ago

TLPPF

Telix Sets August Investor Call for H1 2026 Results

Telix Pharmaceuticals ( ($AU:TLX) ) has shared an announcement. Telix Pharmaceuticals will release its financial results for the...

25d ago

Citi’s Sutcliffe Reiterates Buy on Telix as Strong Precision Medicine Sales and R&D Progress Support Unchanged $31 Price Target

Laura Sutcliffe, an analyst from Citi, maintained the Buy rating on Telix Pharmaceuticals. The associated price target remains...

1M ago

Telix Lifts Q2 Revenue to US$247m as Radiopharma Pipeline Advances

The latest update is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix reported Q2 2026 group revenue of...

1M ago

Telix trims potential dilution as conditional share rights lapse

Telix Pharmaceuticals ( ($AU:TLX) ) just unveiled an announcement. Telix Pharmaceuticals has reported the lapse of several tranches...

2M ago

Telix Pharmaceuticals Issues New Shares After Conversion of Unquoted Securities

Telix Pharmaceuticals ( ($AU:TLX) ) just unveiled an announcement. Telix Pharmaceuticals has reported the issue of 83,750 new...

2M ago

Telix Seeks ASX Quotation for Additional Ordinary Shares

Telix Pharmaceuticals ( ($AU:TLX) ) has issued an announcement. Telix Pharmaceuticals has applied to the ASX for quotation...

2M ago

Telix Pharmaceuticals announces Health Canada approval of Illuccix

Telix Pharmaceuticals announces that Health Canada has approved the use of Illuccix in selecting patients for PSMA1-targeted radionuclide...

2y ago

Telix Pharmaceuticals announces first patient dosed in Phase II CA-NINE trial

Telix Pharmaceuticals announces that the first patient has been dosed in a Phase II trial exploring the clinical...

2y ago

Telix Pharmaceuticals to acquire RLS

Telix Pharmaceuticals and RLS, America’s only Joint Commission-accredited radiopharmacy network distributing PET1, SPECT2 and therapeutic radiopharmaceuticals, announced an...

2y ago

Telix announces Cardinal Health as U.S. commercial distributor for Zircaix

Telix Pharmaceuticals has selected Cardinal Health as a commercial radiopharmaceutical distributor to supply finished unit doses of its...

2y ago

CAH

TLX FAQ

What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?

Telix Pharmaceuticals Ltd. lowest share price was AU$8.26 and its highest was AU$19.07 in the past 12 months.

What is Telix Pharmaceuticals Ltd.’s market cap?

Telix Pharmaceuticals Ltd.’s market cap is AU$5.31B.

When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?

Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Feb 19, 2027 which is in 178 days.

How were Telix Pharmaceuticals Ltd.’s earnings last quarter?

Telix Pharmaceuticals Ltd. released its earnings results on Aug 19, 2026. The company reported AU$0.238 earnings per share for the quarter, beating the consensus estimate of AU$0.028 by AU$0.21.

Is Telix Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Telix Pharmaceuticals Ltd. pay dividends?

Telix Pharmaceuticals Ltd. does not currently pay dividends.

What is Telix Pharmaceuticals Ltd.’s EPS estimate?

Telix Pharmaceuticals Ltd.’s EPS estimate is 0.02.

How many shares outstanding does Telix Pharmaceuticals Ltd. have?

Telix Pharmaceuticals Ltd. has 339,784,300 shares outstanding.

What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?

Telix Pharmaceuticals Ltd. reported an EPS of AU$0.238 in its last earnings report, beating expectations of AU$0.028. Following the earnings report the stock price went up 3.207%.

Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in AU:TLX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Telix Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

25.10%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Telix Pharmaceuticals Ltd.

Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates. TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases. In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer. For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer. Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations. This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.

Telix Pharmaceuticals (TLX) Earnings & Revenues

Historic Earnings Reports

TLX Company Deck

TLX Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call highlighted multiple strong commercial and clinical positives: double‑digit revenue growth (H1 revenue $477M, +22% YoY), robust Precision Medicine momentum (~$390M, +27% YoY), improving margins, a solid cash position ($252M), near-term regulatory catalysts (Pixclara PDUFA on 11 Sep) and advancement of Phase III therapeutic programs and the BiPASS study. Offsetting these are material regulatory uncertainties (notably the Zircaix CRL and required resubmission to address third‑party manufacturing deficiencies), timing risk for European approvals, higher near‑term R&D spend ($230M–$270M guidance) and competitive/reimbursement dynamics. Overall, the highlights — including strong commercial execution, product launches, pipeline progress and strategic partnerships — materially outweigh the lowlights, though execution against regulatory milestones and funding of increased R&D spend remain key watch items.View all AU:TLX earnings summaries

TLX Stock 12 Month Forecast

Average Price Target

AU$25.17

▲(71.71% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"AU$8","14":"AU$14","20":"AU$20","26":"AU$26","32":"AU$32"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.17222222222222,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$25.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,14,20,26,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.21,15.501538461538463,16.793076923076924,18.084615384615386,19.376153846153848,20.66769230769231,21.95923076923077,23.25076923076923,24.542307692307695,25.833846153846153,27.12538461538462,28.416923076923077,29.70846153846154,{"y":31,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.21,15.053247863247863,15.896495726495727,16.73974358974359,17.582991452991454,18.426239316239318,19.26948717948718,20.112735042735043,20.955982905982907,21.799230769230768,22.642478632478632,23.485726495726496,24.328974358974357,{"y":25.17222222222222,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.21,14.57846153846154,14.946923076923078,15.315384615384616,15.683846153846154,16.052307692307693,16.42076923076923,16.78923076923077,17.157692307692308,17.526153846153846,17.894615384615385,18.263076923076923,18.63153846153846,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.15,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.48,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.76,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.57,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.02,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.02,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.21,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >